In the News

Memorial Sloan Kettering Cancer Center chemist Samuel J. Danishefsky will be honored with three major awards this spring. Dr. Danishefsky is the incumbent of a Eugene W. Kettering Chair and a member of the Molecular Pharmacology and Chemistry Program in the Sloan Kettering Institute.

The inaugural Vilcek Prize in Biomedical Research has been awarded by The Vilcek Foundation to Joan Massagué, Chairman of the Sloan Kettering Institute's Cancer Biology and Genetics Program.

Scientists at Sloan Kettering Institute have discovered that the α6ß4 integrin, one of several receptor proteins, plays a key role in signaling for the formation of new blood vessels for a tumor, a process called tumor angiogenesis. By blocking the signaling activity of the α6ß4 subunit of this integrin on vascular cells, researchers found they could slow the growth of tumors.

In recognition of his contributions in basic science related to cancer research, Sloan Kettering Institute Director Thomas J. Kelly has been awarded the 2004 Alfred P. Sloan, Jr. Prize by the General Motors Cancer Research Foundation.

NEW YORK, September 21, 2003 - New research from Memorial Sloan Kettering Cancer Center (MSKCC), Cornell University, and The University of Connecticut describes a novel way of producing therapeutic nerve cells that can cure mice with Parkinson's-like disease. The work, which will be published in the October issue of Nature Biotechnology (available online September 21), provides the first evidence that cloned cells can cure disease in an animal model.